Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06780111 · ClinicalTrials.gov registry record · Phase 1
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
A Phase 1 study of Esophageal Squamous Cell Carcinoma, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 298
- Enrollment target
- 20
- Study locations
NCT06780111 is a Phase 1 study of Esophageal Squamous Cell Carcinoma that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 298 participants, below the 367-participant average among 22 other Esophageal Squamous Cell Carcinoma trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06780111, a Phase 1 study of Esophageal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 298 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unresectable, which means it has spread into tissue near where it started and cannot be completely removed by surgery, or metastatic, which means it has spread to other body parts. Available treatments for these types of ESCC include pembrolizumab and chemotherapy. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. Researchers want to learn about giving pembrolizumab and investigational agents, with or without chemotherapy to treat ESCC. Ifinatamab deruxtecan (I-DXd), is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goal of this study is to learn about the safety of investigational agents and pembrolizumab with or without chemotherapy and if people tolerate them. Researchers also want to learn how cancer responds (gets smaller or goes away) to the study treatments.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL I-DXd
- DRUG Leucovorin
- DRUG Levoleucovorin
- DRUG 5-Fluorouracil (5-FU)
Study Locations (20)
Region M. de Santiago
- FALP ( Site 1400) - Santiago
- Centro de Oncología de Precisión ( Site 1402) - Santiago
- Clínica UC San Carlos de Apoquindo ( Site 1403) - Santiago
- Bradfordhill ( Site 1401) - Santiago
Other
- Bradford Hill Norte ( Site 1405) - Antofagasta
- Pitie Salpetriere University Hospital ( Site 9102) - Paris
- Haematologisch-Onkologische Praxis Eppendorf Facharztzentrum Eppendorf - Hope ( Site 1807) - Hamburg
Pennsylvania
- UPMC Hillman Cancer Center ( Site 1904) - Pittsburgh
Rio Grande do Norte
- Liga Norte Riograndense Contra o Cancer ( Site 1301) - Natal
Rio Grande do Sul
- Hospital Nossa Senhora da Conceicao ( Site 1300) - Porto Alegre
Los Lagos Region
- Clínica Puerto Montt ( Site 1406) - Port Montt
Anhui
- The Second Affiliated Hospital of Anhui Medical University ( Site 9511) - Hefei
Beijing Municipality
- Beijing Cancer Hospital ( Site 9500) - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2032-01-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06780111
The ClinicalTrials.gov registry entry for NCT06780111 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 367-participant average among 22 other Esophageal Squamous Cell Carcinoma trials with a reported enrollment target (19% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06780111 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Region M. de Santiago, Other, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06780111 about?
NCT06780111 is a clinical study titled "Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)". Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unre...
What is the current status of trial NCT06780111?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 298 participants. The study started on 2025-07-30. Estimated completion is 2032-01-04.
What conditions does trial NCT06780111 study?
This clinical trial studies the following conditions: Esophageal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06780111?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), I-DXd (BIOLOGICAL), Leucovorin (DRUG), Levoleucovorin (DRUG), 5-Fluorouracil (5-FU) (DRUG).
Who is sponsoring clinical trial NCT06780111?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06780111 being conducted?
This trial has 20 study locations across Pennsylvania, Rio Grande do Norte, Rio Grande do Sul, Los Lagos Region, Region M. de Santiago. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RECRUITING · Phase 1
-
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.